LONDON–(BUSINESS WIRE)– Australia and New Zealand Banking Group Issue of EUR 750,000,000.00 Floating Rate Notes due March 2027 Series No 2188 Tranche No 1 ISSUE NAME. Our Ref. MV9448 ISIN Code. XS3304302063 INTEREST AMT PER DENOM. CURRENCY CODE. EUR DAY BASIS. Actual/360 (A004) NUM OF DAYS. 91 INTEREST RATE. 2.49563 PCT VALUE DATE. 21/09/2026 INTEREST PERIOD. 22/06/2026 TO 21/09/2026 EUR 1,000.00 IS EUR 6.31 POOL FACTOR. N/A
Author: sHq_LoGiNz
PARIS–(BUSINESS WIRE)– TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) and Mistral announce a 3-year joint program representing an investment of more than €100 million aimed at developing a new generation of frontier AI models to support TotalEnergies’ geosciences experts in the exploration, characterization and development of oil and gas reservoirs. Driving Innovation by Combining AI, Geoscience Expertise and Subsurface Data This partnership will draw on the latest advances in artificial int
LONDON–(BUSINESS WIRE)– Re: Darrowby No 6 PLC GBP 500,000,000.00 MATURING: 21-Sep-2071 ISIN: XS2893515150 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Jun-2026 TO 21-Sep-2026 HAS BEEN FIXED AT 4.25 PCT DAY BASIS: ACTUAL/365(GBP) INTEREST PAYABLE VALUE 21-Sep-2026 WILL AMOUNT TO: GBP 5,327,971.04 PER GBP 503,113,100.00 DENOMINATION
LONDON–(BUSINESS WIRE)– Re: HOPS HILL NO 5 GBP 320,492,000.00 MATURING: 21-Jun-2056 ISIN: XS3102045369 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 21-Aug-2026 TO 21-Sep-2026 HAS BEEN FIXED AT 4.47 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 21-Sep-2026 WILL AMOUNT TO: GBP 1,259,161.11 PER GBP 331,958,678.99 DENOMINATION
PARIS–(BUSINESS WIRE)–Regulatory News: ALIKO Scientific (Ikonisys SA – Euronext Growth Paris : ALIKO), groupe international des sciences de la vie dédié au diagnostic oncologique intégré, annonce le lancement du projet Probantes au Brésil, la constitution en cours de Probantes Ltda, une nouvelle unité commerciale brésilienne détenue à 100 % par Aliko Scientific Srl, ainsi que la signature d’un accord de coopération industrielle stratégique avec Biodetecta – Life Science Ltda. Francesco Trisol
PARIS–(BUSINESS WIRE)–Regulatory News: ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, announces the launch of the Probantes project in Brazil, the ongoing incorporation of Probantes Ltda, a new Brazilian business unit wholly owned by Aliko Scientific Srl, and the signing of a strategic industrial cooperation agreement with Biodetecta – Life Science Ltda. Francesco Trisolini, CEO of Aliko Scienti
MONTPELLIER, France & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) (« la Société ») société pionnière de biotechnologie au stade clinique, spécialisée dans le développement de nouvelles thérapies pour restaurer, traiter et prévenir les troubles de la perte auditive, annonce la réalisation aujourd’hui du regroupement des actions composant le capital social de la Société, tel que décidé par décision du Directeur Général du 27 juillet 2026, suivant subdéléga
MONTPELLIER, France & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) (“the Company”), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces the completion of the reverse share split of the shares composing the Company’s share capital, as decided by the Chief Executive Officer on July 27th, 2026, following sub-delegation granted by the Board o
LYON, France–(BUSINESS WIRE)–Regulatory News: MaaT Pharma (EURONEXT : MAAT – la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem Therapies™ (MET) visant à améliorer la survie des patients atteints de cancer grâce à la modulation du système immunitaire, annonce aujourd’hui avoir été informée par le CHMP de l’Agence européenne des médicaments (EMA) d’une « tendance négative » de vote à l’issue de l’audition orale, dans le ca
LYON, France–(BUSINESS WIRE)—- $MAAT–MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 Following Re-Examination for its Conditional Marketing Authorization Application in Europe
